Skip to main content
Premium Trial:

Request an Annual Quote

GenomeWebinars: Recent

May
18
2021

Sponsored by Bio-Rad

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.  

Dr. Frank Middleton of SUNY (State University of New York) Upstate Medical University has helped direct weekly saliva screening for this program since August 202. This has translated into performing more than a million tests to date, often exceeding 20,000 tests per day. Dr. Middleton has also been actively engaged in monitoring for the emergence of mutations in the testing network using whole-genome viral sequencing. 

In this webinar, Dr. Middleton will provide an overview of the process involved in taking an idea for a better qPCR assay from the bench to the bedside and beyond, in the effort to help reduce the spread of SARS-CoV-2. 

Dr. Middleton will also review lessons learned from the US Food and Drug Administration Emergency Use Authorization process, as well as best practices for resource and logistical management of a state-wide surveillance operation. 

Sponsored by

May
13
2021

Sponsored by LGC SeraCare Life Sciences

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

In this webinar, James Kirby, Director of the Clinical Microbiology Laboratory at Beth Israel Deaconess Medical Center, will discuss his lab’s experience establishing quantitative SARS-CoV-2 viral load testing, the clinical relevance of limits of detection and viral load, and the need to benchmark against a universal standard to allow cross-comparison of SARS-CoV-2 detection methods. He will also discuss the importance of validating the clinical sensitivity of SARS-CoV-2 testing platforms.  

Russell Garlick, Chief Scientific Officer LGC SeraCare, will present the technologies used to advance reference materials for assay standardization.

The webinar will include a 15-minute Q&A session. 

Sponsored by

field_file_image_alt_text_value
May
10
2021

Sponsored by MeMed

Predicting COVID-19 Severity: Leveraging the Host Immune Response to Identify High-Risk Patients and Improve Outcomes

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. Clinicians face the difficult challenge of patient prioritization, identifying which patients to admit and how to effectively triage them within emergency room and hospital settings, and which patients can safely get the care they need at home, in isolation. 

Accurately predicting which COVID-19 patients are at risk of severe disease and deterioration, as well as personalized management of critically ill patients, remains challenging due to the heterogeneous nature of the virus and the limitations of available diagnostic tools. Today, however, novel host immune response technologies are yielding clues on how to best triage COVID-19 patients, showing promise in changing the paradigm in acute care patient management. 

Please join 360Dx and MeMed for a discussion with a panel of international experts on recent advances in the technologies used to probe the host immune response to infections, including COVID-19. Panelists will share new research and insights from their experiences on how predictive biomarkers – and the actionable information they provide – can potentially be used in clinical practice to enable more accurate, rapid diagnoses and timely interventions that can help reduce ICU admissions, the need for ventilation and, ultimately, mortality.

This discussion will cover: 

●      Recent prospective data on the potential utility of a host immune signature, which combines three biomarkers (TRAIL, IP-10, CRP), as a valuable resource for predicting disease severity and progression; 

●      How utilizing IP-10 as a biomarker in real-world settings can aid in monitoring inflammatory status and personalizing treatment strategies for patients with severe COVID-19; 

●      The applications of host immune response technologies in easing the burdens on healthcare systems presented by COVID-19 as well as future pandemics.

Sponsored by

May
07
2021

Sponsored by Foundation Medicine

Webinar Test 2 - Predicting COVID-19 Severity: Leveraging the Host Immune Response to Identify High-Risk Patients and Improve Outcomes

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. Clinicians face the difficult challenge of patient prioritization, identifying which patients to admit and how to effectively triage them within emergency room and hospital settings, and which patients can safely get the care they need at home, in isolation.

Accurately predicting which COVID-19 patients are at risk of severe disease and deterioration, as well as personalized management of critically ill patients, remains challenging due to the heterogeneous nature of the virus and the limitations of available diagnostic tools. Today, however, novel host immune response technologies are yielding clues on how to best triage COVID-19 patients, showing promise in changing the paradigm in acute care patient management. 

Please join 360Dx and MeMed for a discussion with a panel of international experts on recent advances in the technologies used to probe the host immune response to infections, including COVID-19. Panelists will share new research and insights from their experiences on how predictive biomarkers – and the actionable information they provide – can potentially be used in clinical practice to enable more accurate, rapid diagnoses and timely interventions that can help reduce ICU admissions, the need for ventilation and, ultimately, mortality.

This discussion will cover:  

●      Recent prospective data on the potential utility of a host immune signature, which combines three biomarkers (TRAIL, IP-10, CRP), as a valuable resource for predicting disease severity and progression; 

●      How utilizing IP-10 as a biomarker in real-world settings can aid in monitoring inflammatory status and personalizing treatment strategies for patients with severe COVID-19;  

●      The applications of host immune response technologies in easing the burdens on healthcare systems presented by COVID-19 as well as future pandemics.

Sponsored by

Apr
29
2021

Sponsored by Co-Diagnostics

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

CRL recently announced a partnership with Walgreens, offering consumers the convenience of self-collecting COVID-19 saliva tests in their own homes without supervision. Dr. Fehling will detail some of the ways she has been able to adapt her labs to usher in a new era of accessible PCR testing.

Accompanying Dr. Fehling will be Masen Christensen, Senior Design Engineer at Co-Diagnostics, who is responsible for ongoing in silico inclusivity and exclusivity analyses used by the CRL/Walgreens partnership and for monitoring all strains and mutations of SARS-CoV-2.

Christensen will summarize the results of these analyses and outline how to achieve high levels of specificity in saliva PCR by virtually eliminating primer-dimers and the necessity for a fluorescent probe by using the CoPrimer structure developed by Co-Diagnostics.

Attendees of this webinar will learn:

  • How Clinical Reference Labs is able to provide non-invasive and highly accurate saliva PCR tests for at-home collection
  • The results of ongoing in silico inclusivity and exclusivity analyses on COVID-19 mutations and emerging strains
  • How new PCR science and technology is enabling and expanding the applications and accessibility of PCR tests

Sponsored by

Apr
16
2021

Sponsored by Thermo Fisher Scientific

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

When vaccines are broadly implemented and SARS-CoV-2 positivity rates are lower, pooled testing may become more widespread as a means to prevent future outbreaks. There may also be greater adoption of serology tests to monitor people who have been vaccinated, as well as the potential for more decentralized testing. Furthermore, clinical labs and test developers will need to adjust for increases in testing volumes for segments that were neglected during the pandemic.

This virtual roundtable discussion will assemble a panel of industry stakeholders, including clinical and public labs, to discuss how they are planning for a post-vaccine testing landscape.

The session will include a live Q&A in which attendees can post questions to our panelists.

Sponsored by

field_file_image_alt_text_value
Apr
13
2021

Sponsored by Beckman Coulter Life Sciences

An Opportunity Arises from the Pandemic: The Promise of Targeted NGS for SARS-CoV-2 Detection

Mitigation of the SARS-CoV-2 pandemic will continue to require innovative solutions. This webinar will outline how Fry Laboratories rapidly redeployed a next-generation sequencing (NGS) pipeline originally created for the detection and identification of bacterial, eukaryotic, and fungal infections in response to SARS-CoV-2.

NGS offers unbiased microbial detection while leveraging the analytical and cost-effectiveness advantages of PCR-based methods. This represents a relatively untapped resource, but the approach creates several unique implementation challenges and solutions. 

In this webinar, Jeremy Ellis of Fry Laboratories will describe an ultra-high-throughput SARS-CoV-2 detection assay for as many as 1,152 saliva samples using a single MiSeq Micro flow cell. The assay uses PCR to simultaneously amplify, index, and adapt SARS-CoV-2 specific regions for sequencing. This method enables a significantly higher assay throughput than what is realized by standard PCR-based approaches and allows for the inclusion of additional targets for relevant SARS-CoV-2 mutations of interest as needed. 

Dr. Ellis will describe how his work at Fry Laboratories, in collaboration with Beckman Coulter Life Sciences, is using economical and nimble NGS-based assays to fill gaps in its capabilities as it works to reduce the impact of SARS-CoV-2. 

He will also discuss how the combined capabilities across prokaryotic, eukaryotic, and viral detection using a unified NGS-based technology enabled by scalable solutions represents a new horizon in molecular microbiology.

Sponsored by

Apr
06
2021

Sponsored by Beckman Coulter

Reducing COVID-19 Infection Rates at a University Campus with Mass Screening

As the number of global cases of COVID-19 surpass 100 million, experts continue to call for rigorous population testing as a necessary measure to contain the spread of this infection that can move swiftly and silently.

In this webinar session, Dr. David Harris and Dr. Ryan Sprissler, who led the student and employee testing program at University of Arizona, will discuss how the university remained physically open with nearly 25% of its population on campus, while keeping infection rates below 2 percent. This is particularly challenging with a student body that can be asymptomatic and is not rigorous about social distancing and masking compliance.

To keep infection rates low, the University of Arizona has implemented frequent testing, rapid return of results and strict compliance with regards to quarantining when infection is detected.

JOIN THIS WEBINAR TO LEARN MORE ABOUT:

  • The importance of frequent testing to locate and isolate contagious individuals to reduce infection rates;
  • Guidance on developing a mass screening program: how often and who to test; and how to deliver results in time to prevent the spread of infection;
  • Learnings from experiences on running a mass screening program in a university with a largely young population;
  • The successful protocol to run thousands of COVID-19 antigen tests every day with supplemental PCR and antibody testing;
  • The successful framework to centralize specimen collection sites to increase testing compliance and optimize for high throughput testing and stringent QC oversight.

Sponsored by

field_file_image_alt_text_value
Mar
31
2021

Sponsored by Millipore Sigma

Development and Commercialization of a Novel CRISPR-Based SARS CoV-2 Test

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test. 

Mammoth Biosciences developed the test in response to the COVID-19 pandemic. The company was one of one of seven chosen to receive funding through the National Institutes of Health’s RADx program to support development and commercialization of the test.  

Tim Patno, vice president of product development at Mammoth Biosciences, will discuss Mammoth’s novel CRISPR-based technology as well as the company’s partnership with MilliporeSigma to manufacture its DETECTR BOOST SARS-CoV-2 Reagent Kit. Patno will discuss the steps Mammoth took to vet and choose a manufacturing partner within the context of commercializing a novel in vitro diagnostic.

Attendees will learn:

  • The basic technology and platform of the CRISPR-based SARS-CoV-2 DETECTR test.
  • The steps in the commercialization process of an IVD; from scope of work through to development, engineering, validation, and closing.
  • Advantages of working with a commercial partner to expedite kit development and launch.

 

Sponsored by

field_file_image_alt_text_value
Mar
29
2021

Sponsored by Thermo Fisher Scientific

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines. As such, global surveillance plays a central role in proactively managing pathogens such as SARS-CoV-2, the virus that causes COVID-19. 

Similarly, local genetic surveillance offers an opportunity to understand the evolution of the virus in the community and take actions to manage transmission and monitor evolution at the local level. Robust data about which strains are common, where they are spreading, how their symptoms differ, when new variants are emerging, and more can enable communities, states and countries to better prepare for their arrival. 

Vaccine and test manufacturers are guided by this information as well, cutting weeks or even months from any response they need to make. Genetic surveillance already exists on a large scale to enable scientists to determine which influenza strains are appropriate targets for each year’s flu vaccines, and a similar effort will be needed to make sense of SARS-CoV-2 and its evolving strains.

This webinar will focus on genetic surveillance of the emerging variants of SARS-CoV-2, provide an update on the trending variants, explain the risks of the rise of escape mutants, and outline best practices to establish both global and local surveillance programs, including technologies used for monitoring viral evolution, such as next-generation sequencing.

Learning Objectives:

  • Hear from a leading expert in infectious disease epidemiology regarding emerging variants of SARS-CoV-2.
  • Receive up-to-date information on the state of emerging variants, the impact of selective pressures, and the associated evolutionary advantage conferred to the virus.
  • Learn about best practices in standing up global and community surveillance efforts.
  • Hear from a thought leader in molecular pathology who harnessed his expertise in molecular genetics to contribute to surveillance efforts on a local level.
This webinar is the second in a two part series on Public Health and Emerging SARS-CoV-2 Variants: Implications and Responses.

Sponsored by

field_file_image_alt_text_value
Mar
18
2021

Sponsored by Thermo Fisher Scientific

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Viruses mutate as they strive to thrive in response to selective pressures. For molecular diagnostic assays to serve in the management of viral transmission, they need to be designed anticipating the emergence of mutations.

This webinar will focus on the impact of emerging viral variants of SARS-CoV-2 on molecular diagnostic testing. In the first part of the session, Dr. Alan McNally will share how the B.1.1.7 variant was discovered in the United Kingdom, highlight the role played by a molecular diagnostic assay in its detection, and discuss design principles that aid in the development of effective and robust molecular diagnostic assays. In addition, Dr. McNally will discuss some of the clinical data associated with the B.1.1.7 strain as well as the importance of early identification of this variant of concern.

In the second part of the session, Dr. Emmanuel André will discuss his approach to identifying specific SARS-CoV-2 variants using a targeted mutation panel as a reflex test following a suspect clinical variant result. Dr. Andre will provide details about the mutation panel composition as well as the advantages of using this approach for wide-scale SARS-CoV-2 surveillance.

Learning Objectives:

  • Hear the story of detecting the B.1.1.7 variant (UK variant) from a world-leading epidemiologist.
  • Understand the importance of early detection of viral variants and the impact of emerging variants on global response efforts.
  • Learn about molecular diagnostic assay design principles to safeguard against unexpected false results due to mutations and the means to monitor assays as early indicators of emerging variants.
  • Learn about the S-gene advantage with B.1.1.7, the role of the S-gene dropout, and the value of a targeted mutation panel as a reflex tool as follow up for a suspected clinical variant.
This webinar is part 1 of a 2 part series on Public Health and Emerging SARS-CoV-2 Variants: Implications and Responses.

Sponsored by

field_file_image_alt_text_value
Feb
26
2021

Sponsored by Agena Bioscience

Responding to Emerging SARS-CoV-2 Variants: The Impact on Existing Diagnostic Testing and the Clinical Utility of Differentiation Assays

As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.  Understanding the impact of these variants on molecular testing methods and how labs can address this added complexity is important to managing the diagnostic response to the ongoing pandemic.

In this webinar Dr. Martin Stürmer of IMD Labor Frankfurt will discuss the effects of emerging SARS-CoV-2 variants on diagnostic methods and the clinical utility of detecting and discriminating them. Thomas Alef of Seq-IT will then present how his clinical lab was able to react to the emergence of new, often more contagious, variants of the virus by rapidly designing a highly multiplexed SARS-CoV-2 variant panel using the low-cost, high-throughput MassArray System from Agena Bioscience.

Sponsored by

Feb
24
2021

Sponsored by SCHOTT MINIFAB

Case Study: Rapid Development and Manufacturing Scaleup of a Point-of-Care COVID-19 Test

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints. 

This has been the case with the development and quick manufacturing scaleup of Qorvo's COVID-19 test. Primary among these challenges has been acquiring and coordinating broad multidisciplinary expertise among Qorvo’s team of people and partners; successfully cultivating the capabilities and culture to be flexible and innovative in face of extreme uncertainty; and, lastly, developing access to broad manufacturing scalability to accommodate the flexibility needed from product development to high-volume manufacturing.

This webinar will present a case study outlining Qorvo's path in developing and commercializing its COVID-19 test. In so doing, participants can expect to learn:

  • Key challenges of diagnostic test development, both anticipated and unanticipated
  • Relevant factors during development that are important to eventual successful commercialization
  • Perspective on the need for development and manufacturing partners and what capabilities they should possess.

Sponsored by

field_file_image_alt_text_value
Feb
23
2021

Sponsored by Thermo Fisher Scientific

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. Labs face new challenges such as having to process large volumes of samples with a quick turnaround time, the constant risk of falling into backlog, and the possibility of loss of reimbursement (for certain samples). But what happens after the surge, when infection rates decline but testing will still be a necessary component of managing the virus? 

During this presentation, Weston Hymas of ARUP Laboratories will discuss the clinical validation of a SARS-CoV-2 sample pooling protocol that can be used to exponentially increase testing efficiency, enabling a higher volume of sample processing in lower prevalence rate populations. This method can be implemented by clinical labs for routine processing of samples from populations with low infection rates. 

Sponsored by

field_file_image_alt_text_value
Dec
15
2020

Sponsored by UgenTec

Case Study: Deployment of High-Throughput SARS-CoV-2 Testing at UC Davis

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control. These efforts are being integrated with the Healthy Davis Together initiative, which is providing free testing for everyone in the City of Davis. The goal is to provide at least weekly testing combined with more frequent strategic testing. This requires rapid data analysis software that minimizes the time needed to accurately call, certify, and return results. 

In this webinar, Prof. Richard W. Michelmore, director of the Genome Center at UC Davis, will describe how his team based its approach on workflows developed in the agricultural biotechnology sector that are capable of cost-effectively generating millions of data points per day. 

Prof. Michelmore will discuss details of the entire workflow, from sample collection through to a data management system that his team developed that uses Ugentec’s Fastfinder software. 

After Dr. Michelmore’s presentation, James Grayson of UgenTec will briefly discuss FastFinder, which allows labs and assay providers to build sample-to-result workflows. 

After this, Ross Higgins of LGC, Biosearch Technologies will briefly introduce how their instrumentation solutions support very large scale screening initiatives.

The presentations will be followed by an interactive Q&A session with attendees.

Sponsored by

field_file_image_alt_text_value